Antonio Landi, Mirvat Alasnag, Dik Heg, Enrico Frigoli, Fazila Tun Nesa Malik, Ivan Gomez-Blazquez, Suzanne Pourbaix, Alaide Chieffo, Christian Spaulding, Fermin Sainz, Helen Routledge, Giuseppe Andò, Luca Testa, Alessandro Sciahbasi, Hussain Contractor, Nigel Jepson, Juan Mieres, Syed Saqib Imran, Husam Noor, Pieter C Smits, Marco Valgimigli
IMPORTANCE: Abbreviated dual antiplatelet therapy (DAPT) reduces bleeding with no increase in ischemic events in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI). OBJECTIVES: To evaluate the association of sex with the comparative effectiveness of abbreviated vs standard DAPT in patients with HBR. DESIGN, SETTING, AND PATIENTS: This prespecified subgroup comparative effectiveness analysis followed the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated vs Standard DAPT Regimen (MASTER DAPT) trial, a multicenter, randomized, open-label clinical trial conducted at 140 sites in 30 countries and performed from February 28, 2017, to December 5, 2019...
January 1, 2024: JAMA Cardiology